Neuren Pharma shares jump to a three-month high as it NNZ-2591 drug shows promise its second Phase 2 trial to treat Pitt Hopkins Syndrome.Wilsons Advisory reiterates its Overweight rating while lifting its price target by over 10pc to $30 as Neuren shares soar to $23.07 after its investor presentation.
"This data provides a second independent validation of NNZ-2591 as a potential treatment for cognitive impacts in orphan neurodevelopmental disorders," says Wilsons analyst Melissa Benson."As we have consistently noted, we assess the opportunity for NNZ-2591 to be at least five-fold that of DAYBUE owing to its superior tolerability and apparent efficacy profile with a strong intellectual property moat."The consistency of this data gives us conviction in the upcoming 3Q and CY25 readouts of NNZ-2591 in Angelman and Prader Willi syndromes, respectively, leading us to de-risk the Phase II programs. "Dr Benson says this should elevate investor’s confidence in the reality of NNZ-2591 as a future blockbuster and appetite to reflect that in valuations.
- Forums
- ASX - By Stock
- Ann: Phase 2 trial shows significant improvements in Pitt Hopkins
Neuren Pharma shares jump to a three-month high as it NNZ-2591...
-
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B |
Open | High | Low | Value | Volume |
$14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $13.99 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.07 | 6644 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 13.990 |
1 | 300 | 13.970 |
1 | 1432 | 13.950 |
2 | 1230 | 13.900 |
1 | 720 | 13.890 |
Price($) | Vol. | No. |
---|---|---|
14.420 | 175 | 1 |
14.500 | 2985 | 2 |
14.800 | 2850 | 2 |
14.860 | 500 | 1 |
14.960 | 445 | 1 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
NEU (ASX) Chart |